Two body scattering length of Yukawa model on a lattice

The extraction of scattering parameters from Euclidean simulations of a Yukawa model in a finite volume with periodic boundary conditions is analyzed both in non relativistic quantum mechanics and in quantum field theory.Comment: 4 pages, talk at "18th International IUPAP conference on Few Body Problems in Physics" (Sao Paulo, August 2006

Nuclear models on a lattice

We present the first results of a quantum field approach to nuclear models obtained by lattice techniques. Renormalization effects for fermion mass and coupling constant in case of scalar and pseudoscalar interaction lagrangian densities are discussed.Comment: 4 pages - 7 figures ; Invited talk to QCD 05: 12th International QCD Conference, 4-9 Jul 2005, Montpellier, France ; To appear in Nucl. Phys. B (Proc. Suppl.

The Nuclear Yukawa Model on a Lattice

We present the results of the quantum field theory approach to nuclear Yukawa model obtained by standard lattice techniques. We have considered the simplest case of two identical fermions interacting via a scalar meson exchange. Calculations have been performed using Wilson fermions in the quenched approximation. We found the existence of a critical coupling constant above which the model cannot be numerically solved. The range of the accessible coupling constants is below the threshold value for producing two-body bound states. Two-body scattering lengths have been obtained and compared to the non relativistic results.Comment: 15 page

Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis

© 2015 Elsevier Inc. The development of effective prophylactic strategies to prevent leishmaniasis has become a high priority. No less important than the choice of an antigen, the association of an appropriate adjuvant is necessary to achieve a successful vaccination, as the majority of the tested antigens contain limited immunogenic properties, and need to be supplemented with immune response adjuvants in order to boost their immunogenicity. However, few effective adjuvants that can be used against leishmaniasis exist on the market today; therefore, it is possible to speculate that the research aiming to identify new adjuvants could be considered relevant. Recently, Agaricus blazei extracts have proved to be useful in enhancing the immune response to DNA vaccines against some diseases. This was based on the Th1 adjuvant activity of the polysaccharide-rich fractions from this mushroom. In this context, the present study evaluated purified fractions derived from Agaricus blazei as Th1 adjuvants through in vitro assays of their immune stimulation of spleen cells derived from naive BALB/c mice. Two of the tested six fractions (namely F2 and F4) were characterized as polysaccharide-rich fractions, and were able to induce high levels of IFN-γ, and low levels of IL-4 and IL-10 in the spleen cells. The efficacy of adjuvant action against L. infantum was evaluated in BALB/c mice, with these fractions being administered together with a recombinant antigen, LiHyp1, which was previously evaluated as a vaccine candidate, associated with saponin, against visceral leishmaniasis (VL). The associations between LiHyp1/F2 and LiHyp1/F4 were able to induce an in vivo Th1 response, which was primed by high levels of IFN-γ, IL-12, and GM-CSF, by low levels of IL-4 and IL-10; as well as by a predominance of IgG2a antibodies in the vaccinated animals. After infection, the immune profile was maintained, and the vaccines proved to be effective against L. infantum. The immune stimulatory effects in the BALB/c mice proved to be similar when comparing the F2 and F4 fractions with a known Th1 adjuvant (saponin), though animals vaccinated with saponin did present a slight to moderate inflammatory edema on their hind footpads. In conclusion, the F2 and F4 fractions appear to induce a Th1-type immune response and, in this context, they could be evaluated in association with other protective antigens against Leishmania, as well as in other disease models.Instituto Nacional de Ciencia e Tecnologia em Nano-biofarmaceutica (INCT-Nanobiofar), FAPEMIG (CBB-APQ-00496-11 and CBB-APQ-00819-12), and CNPq (APQ-472090/2011-9, RHAE-456287/2012-4, APQ-482976/2012-8 and APQ-488237/2013-0).Peer Reviewe

Yukawa model on a lattice: two body states

We present first results of the solutions of the Yukawa model as a Quantum Field Theory (QFT) solved non perturbatively with the help of lattice calculations. In particular we will focus on the possibility of binding two nucleons in the QFT, compared to the non relativistic result.Comment: 3 pages, talk at "IVth International Conference on Quarks and Nuclear Physics" (Madrid, June 2006

Renormalisation of quark propagators from twisted-mass lattice QCD at NfN_f=2

We present results concerning the non-perturbative evaluation of the renormalisation constant for the quark field, $Z_q$, from lattice simulations with twisted mass quarks and three values of the lattice spacing. We use the RI'-MOM scheme. $Z_q$ has very large lattice spacing artefacts; it is considered here as a test bed to elaborate accurate methods which will be used for other renormalisation constants. We recall and develop the non-perturbative correction methods and propose tools to test the quality of the correction. These tests are also applied to the perturbative correction method. We check that the lattice spacing artefacts scale indeed as $a^2p^2$. We then study the running of $Z_q$ with particular attention to the non-perturbative effects, presumably dominated by the dimension-two gluon condensate \VEV{A^2} in Landau gauge. We show indeed that this effect is present, and not small. We check its scaling in physical units confirming that it is a continuum effect. It gives a $\sim 4$ contribution at 2 GeV. Different variants are used in order to test the reliability of our result and estimate the systematic uncertainties. Finally combining all our results and using the known Wilson coefficient of \VEV{A^2} we find g^2(\mu^2) \VEV{A^2}_{\mu^2\; CM} = 2.01(11)(^{+0.61}_{- 0.73}) \;\mathrm {GeV}^2 at $\mu=10\, \mathrm{GeV}$, in fair agreement within uncertainties with the value indepently extracted from the strong coupling constant.Comment: 38 pages, 8 tables, 8 figure